Abstract
Abiraterone is an oral, selective, steroidal inhibitor of cytochrome P450(17alpha) being developed by Cougar Biotechnology Inc for the potential treatment of prostate cancer. Phase I clinical trials of abiraterone have been conducted and the design of phase I/II clinical trials is being finalized.
MeSH terms
-
Androgen Antagonists / chemistry
-
Androgen Antagonists / pharmacology
-
Androgen Antagonists / therapeutic use
-
Androstenes
-
Androstenols / chemistry
-
Androstenols / pharmacology
-
Androstenols / therapeutic use*
-
Animals
-
Clinical Trials, Phase I as Topic
-
Enzyme Inhibitors / chemistry
-
Enzyme Inhibitors / pharmacology
-
Enzyme Inhibitors / therapeutic use
-
Humans
-
Licensure
-
Male
-
Molecular Structure
-
NADPH-Ferrihemoprotein Reductase / antagonists & inhibitors*
-
Patents as Topic
-
Prostatic Neoplasms / drug therapy*
-
Treatment Outcome
Substances
-
Androgen Antagonists
-
Androstenes
-
Androstenols
-
Enzyme Inhibitors
-
NADPH-Ferrihemoprotein Reductase
-
abiraterone